Post-marketing study of safety and efficacy of GARDASIL in young Japanese women.

Registry ID

EUCTR2015-002932-42

Source registry

EUCTR

Phase

PHASE4

Sponsor

MSD K.K., a subsidiary of Merck & Co., Inc

Last update

2026-08-16

Conditions

• Human Papillomavirus infection

Summary

To investigate the incidence of HPV types 6, 11, 16 and 18 related CIN 2 and 3, AIS and cervical cancer in Japanese women aged 16 to 26 years old who had been vaccinated with the quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP vaccine and were PCR negative and seronegative at baseline and PCR negative through Month 7 for the relevant HPV type.

View on source registry